Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The role of funding and policies on innovation in cancer drug development

Share :
Published: 3 Feb 2010
Views: 10056
Rating:
Save
Prof Richard Sullivan - European Cancer Research Managers Forum

Professor Richard Sullivan, Chairman of the European Cancer Research Managers Forum, discusses the study he co-authored, reviewing innovation in cancer drug development. To read the paper click here.

Related Videos

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...
Dr Jill Corre - IUCT Oncopole, Toulouse, France
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )
29 Oct 2024
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Dr Elias Mai - Heidelberg University, Heidelberg, Germany
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )
28 Oct 2024
Guiding transplant decisions in multiple myeloma with MRD
Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA
Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )
28 Oct 2024
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...
ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )
18 Oct 2024
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced...
Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )
16 Oct 2024
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy...
Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )
9 Oct 2024
Tusamitamab ravtansine versus docetaxel in previously treated advanced...
Prof Benjamin Besse - Gustave Roussy, Paris, France
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial ( Prof Benjamin Besse - Gustave Roussy, Paris, France )
1 Oct 2024
Cemiplimab monotherapy could be a new treatment option for first line advanced...
Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia
Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients ( Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia )
1 Oct 2024
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...
Prof Salomon Manier - Hospital Center University De Lille, Lille, France
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )
30 Sep 2024

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation